POM-V Prescription Required Companion Animal

Doxycare Flavour 40 mg Tablets for Cats and Dogs

Active ingredient: Doxycycline

Form

Tablet

Species

Cats Dogs

Manufacturer

Ecuphar NV

VMD MA No.

32742/4014

What it's used for

For the treatment of canine ehrlichiosis caused by Ehrlichia canis. Cats For the treatment of respiratory tract infections including rhinitis, tonsillitis...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Doxycycline

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Doxycare Flavour 40 mg Tablets for Cats and Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the treatment of canine ehrlichiosis caused by Ehrlichia canis.
Cats
For the treatment of respiratory tract infections including rhinitis, tonsillitis and
bronchopneumonia caused by Bordetella bronchiseptica, and Pasteurella spp
susceptible to doxycycline.
AN: 02202/2024 and 02205/2024

The dosage is 10 mg doxycycline per kilogram of bodyweight per day.
To ensure a correct dosage, bodyweight should be determined as accurately as
possible to avoid overdosing or underdosing. In order to adjust the dosage, the
tablets can be divided into 2 or 4 equal parts. Place the tablet on a flat surface, with
its scored side facing up and the convex (rounded) side facing the surface. The
dosage can be divided into two daily administrations. The duration of treatment might
be adapted depending on the clinical response, after benefit/risk assessment by the
veterinarian.
DiseaseDosage regimenDuration of treatmentRespiratory tract infection10 mg/kg per day5-10 daysCanine ehrlichiosis10 mg/kg per day28 days

Halves: press down with your thumbs or fingers on both sides of the tablet.
Quarters: press down with your thumb or finger in the middle of the tablet.

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in animals with renal or hepatic insufficiency.
Do not use in animals with diseases associated with vomiting or dysphagia (see also
section 3.6).
Do not use in animals with known photosensitivity (see also section 3.6).
Do not use in puppies and kittens before completion of teeth enamel formation.

Cats and dogs:
Undetermined frequency
(cannot be estimated from the available
data):
Photosensitivity, photodermatitis
Dental discolouration
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Gastrointestinal disorders (e.g. vomiting,
nausea, hypersalivation, oesophageal
irritation, diarrhoea)
1
can occur following tetracycline therapy, after exposure to intense sunlight or
ultraviolet light (See also section 3.3).
use of tetracycline during the period of tooth development.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

Ehrlichia canis infection: treatment should be initiated at the onset of clinical signs.
Complete eradication of the pathogen is not always achieved, but treatment for 28
days generally leads to a resolution of the clinical signs and a reduction of the
bacterial load. A longer duration of treatment, based on a benefit/risk assessment by
the responsible veterinarian, may be required particularly in severe or chronic
ehrlichiosis. All treated patients should be regularly monitored, even after clinical
cure.

Special precautions for safe use in the target species:
Use of the veterinary medicinal product should be based on identification and
susceptibility testing of the target pathogens. If this is not possible, therapy should be
based on epidemiological information and knowledge of susceptibility of the target
pathogens at local/regional level.
Use of the veterinary medicinal product deviating from the instructions given in the
SPC may increase the prevalence of bacteria resistant to doxycycline and may
decrease the effectiveness of treatment with other tetracyclines, due to the potential
for cross-resistance. Use of the veterinary medicinal product should be in accordance
with official, national and regional antimicrobial policies.
Tablets should be administered with food in order to avoid vomiting and to reduce the
likelihood of oesophageal irritation.
The product should be administered with caution to young animals, since
tetracyclines as a class may cause permanent discolouration of the teeth, when
administered during tooth development. However, human literature indicates that
doxycycline is less likely than other tetracyclines to cause these abnormalities, due to
its reduced ability to chelate calcium.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
People with known hypersensitivity to doxycycline or other tetracyclines should avoid
contact with the veterinary medicinal product and personal protective equipment
consisting of gloves should be worn when handling the veterinary medicinal product.
In case of skin irritation, seek medical advice immediately and show the package
leaflet or the label to the physician.
AN: 02202/2024 and 02205/2024
Accidental ingestion, especially by children, may cause adverse reactions such as
emesis. To avoid accidental ingestion, blisters should be inserted back into the outer
packaging and kept in a safe place. In case of accidental ingestion, seek medical
advice immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

Doxycycline should not be used concurrently with other antibiotics, especially
bactericidal drugs such as the ß-lactams. Cross-resistance to tetracyclines can occur.
The half-life of doxycycline is reduced by concurrent administration of barbiturates,
phenytoin and carbamazepine.
Dosage adjustments may be necessary in subjects under anticoagulant therapy, as
tetracyclines depress the plasma activity of prothrombin.
Simultaneous administration of oral absorbents, antacids and preparations including
multivalent cations should be avoided as they reduce doxycycline availability.
AN: 02202/2024 and 02205/2024

This veterinary medicinal product does not require any special storage conditions.
Any remaining tablet portion should be returned to the blister and given at the next
administration.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.